Regorafenib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 40 mg, 80 mg, 120 mg, 160 mg
Reference Brands: Stivarga (USA/EU)
Category:
Oncology Cancer Care
Regorafenib is available in Tablets
and strengths such as 40 mg, 80 mg, 120 mg, 160 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Regorafenib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Regorafenib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Regorafenib is an oral multi-kinase inhibitor used for the treatment of several advanced cancers, including metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. It works by targeting multiple protein kinases involved in tumor growth, angiogenesis, and the tumor microenvironment. By inhibiting vascular endothelial growth factor receptors (VEGFR1, VEGFR2, VEGFR3), TIE2, and oncogenic receptor tyrosine kinases, regorafenib helps block the growth of new blood vessels that tumors require and disrupts signaling pathways that support cancer cell proliferation and survival. This dual action as a kinase inhibitor and anti-angiogenesis agent makes it effective in controlling disease progression in patients with cancers that are resistant to standard therapies. Regorafenib is marketed under the brand name Stivarga and was developed by Bayer. It is taken orally and is typically prescribed under specialist supervision due to the need for careful monitoring of side effects, including hypertension, hand-foot skin reactions, liver toxicity, and gastrointestinal symptoms. The medication provides a targeted therapeutic option for patients with advanced cancers, offering improved disease management and the potential to extend survival in carefully selected patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing